Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Med J Aust ; 174(7): 333-7, 2001 Apr 02.
Artigo em Inglês | MEDLINE | ID: mdl-11346105

RESUMO

OBJECTIVE: To assess the efficacy of an antibiotic protocol to avoid empirical use of third-generation cephalosporins in community-acquired pneumonia (CAP). DESIGN AND SETTING: Retrospective case review of patients with CAP one year after implementing the protocol. Comparison was made with patients with CAP treated at a metropolitan tertiary referral hospital (where use of third-generation cephalosporins was common). PARTICIPANTS: 86 patients (district hospital with an antibiotic protocol) and 72 patients (metropolitan tertiary referral hospital), January - June 1999. OUTCOME MEASURES: Rate of staff adherence to the protocol; patient characteristics associated with poor protocol adherence; demographic and prognostic features of both groups at presentation; duration of intravenous therapy, time to defervescence, length of stay; inpatient mortality rates; and drug cost savings per patient treated according to the protocol. RESULTS: Overall protocol adherence rate was 60%. Patients with penicillin allergy were significantly less likely to receive treatment according to the protocol (P<0.001). At the district hospital, patients were generally older and taking more regular medications. Patients at each hospital had similar prognostic factors and demographic features at presentation. Inhospital mortality (P=0.92; 95% CI, -0.08 to 0.07), duration of fever (P=0.57) and length of stay (P=0.78) were not significantly different between patients treated empirically with penicillin and those treated empirically with third-generation cephalosporins. Treating a patient according to the protocol saved an average of $77.44 in drug costs. CONCLUSION: One year after implementation, our protocol for treating CAP is proving efficacious, although levels of adherence could improve.


Assuntos
Antibacterianos/uso terapêutico , Cefalosporinas/uso terapêutico , Infecções Comunitárias Adquiridas/tratamento farmacológico , Penicilinas/uso terapêutico , Pneumonia/tratamento farmacológico , Adulto , Idoso , Ampicilina/economia , Ampicilina/uso terapêutico , Antibacterianos/economia , Cefazolina/economia , Cefazolina/uso terapêutico , Cefalosporinas/economia , Protocolos Clínicos , Infecções Comunitárias Adquiridas/diagnóstico , Infecções Comunitárias Adquiridas/economia , Infecções Comunitárias Adquiridas/mortalidade , Análise Custo-Benefício , Custos de Medicamentos , Quimioterapia Combinada , Eritromicina/economia , Eritromicina/uso terapêutico , Feminino , Mortalidade Hospitalar , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , New South Wales , Penicilina G/economia , Penicilina G/uso terapêutico , Penicilinas/economia , Pneumonia/diagnóstico , Pneumonia/economia , Pneumonia/mortalidade , Prognóstico , Estudos Retrospectivos , Estatísticas não Paramétricas , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA